BioSpace News Archive

Global Coalition for Adaptive Research, the U.S. Sponsor of REMAP-COVID, announced that Eisai has ended the evaluation of eritoran in the REMAP-COVID study.

CohBar, Inc. announced its virtual participation in the 2022 H.C. Wainwright Global Investment Conference.

Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced presentations at the upcoming 2022 European Congress of Endocrinology (ECE), which is being held May 21-24, 2022, in Milan, Italy.

Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical stage biotechnology company pioneering a new class of medicines that modulate gene expression through selectively targeting the chromatin regulatory system, today announced the Food and Drug Administration (FDA) has placed the Phase 1 dose escalation study of FHD-286 in relapsed and/or refractory acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) on a partial clinical hold.

Gracell Biotechnologies Inc. announced that the management team will participate in and attend one-on-one meetings at three investor conferences in June 2022 as follows:

Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutics, today announced a new patent related to its Drug Delivery System (DDS) platform under development.

Alphatec Holdings, Inc. announced that executive management will participate in the following investor events: Todd Koning, Chief Financial Officer, will present at the Wells Fargo Securities West Coast MedTech Tour on June 2, 2022, at 11:30am PDT.

Olympus announced a strategic co-marketing agreement with Monroe Township, N.J.-based Bracco Diagnostics Inc., the U.S. subsidiary of Bracco Imaging S.p.A., a leading global company in the diagnostic imaging business.

The latest business intelligence studies predict that the global smart healthcare market will expand at a stellar compound annual growth rate of 16.2 % over the forecast period of 2020 to 2027.

The interest for pharmacy benefit management is on the ascent attributable to increment in the quantity of protection suppliers with in-house pharmacy benefit groups to oversee secured populace.